A prospective, multicenter, single-arm, early feasibility study aimed to assess safety and performance of the Leaflex™ Performer in the treatment of patients with symptomatic, severe aortic stenosis.
A prospective, multicenter, single-arm, early feasibility study aimed to assess safety and performance of the Leaflex™ Performer in the treatment of patients with symptomatic, severe aortic stenosis. Subjects will be seen at pre- and post procedure, discharge, 30 days and at 3, 6, 9 and 12 months post procedure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
Change in aortic valve area
assessed by echo
Time frame: Baseline to 3 days
Rate of all-cause mortality and all-cause stroke (VARC 2)
Composite
Time frame: 30 days post procedure
Rate of worsening of aortic regurgitation
by greater than 1 grade
Time frame: Baseline to 30 days
Rate of worsening of aortic regurgitation
by greater than 1 grade
Time frame: Discharge to 30 days
Rate of device related adverse events
Time frame: 12 months
Change in 6 minute walk test
distance (meters)
Time frame: 1, 6 and 12 months
Quality of Life Improvement
measured by KCCQ
Time frame: 1, 6 and 12 months
Quality of Life Improvement
measured by EQ5D
Time frame: 1, 6 and 12 months
Change in aortic valve area
assessed by echo
Time frame: 30 day, 3, 6, 9, 12 months
Change in pressure gradients
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
assessed by echo
Time frame: 30 day, 3, 6, 9, 12 months